Department of Medicine, Olive View-University of California Los Angeles (UCLA) Medical Center, Sylmar, California, USA
Department of Medicine, Olive View-University of California Los Angeles (UCLA) Medical Center, Sylmar, California, USA.
BMJ Open. 2023 Sep 29;13(9):e074354. doi: 10.1136/bmjopen-2023-074354.
Smoking remains the leading preventable cause of death in the USA. Low utilisation of treatments for smoking cessation remains a major barrier for reducing smoking rates. Financial incentives represent an innovative approach to increasing use of therapies for smoking cessation. This paper will describe the rationale and design of the Financial Incentives for Smoking Treatment II (FIESTA II) study, a randomised controlled trial to evaluate the effectiveness and feasibility of goal-directed and outcome-based financial incentives to promote smoking cessation among hospitalised smokers.
We are recruiting adult participants who smoked tobacco in the 30 days prior to initial interview and are contemplating quitting smoking. These participants will come from two hospitals in underserved communities in New York City and Los Angeles. They will be randomised into one of three arms. The first arm consists of goal-directed financial incentives plus enhanced usual care, which includes hospital-directed information about quitting smoking, nicotine replacement therapy and referral to a Quitline. The second arm involves outcome-based financial incentives plus enhanced usual care. The third arm consists of enhanced usual care alone. Multiple phone interviews with the participants will be completed after randomisation to assess smoking cessation. Participants will earn $20 for each follow-up interview completed and $30 for each smoking cessation test completed. Those who are randomised to the financial incentive groups can earn an additional $700. The participants in the outcome-based group will receive payments solely for exhibiting cessation, whereas the participants in the goal-based group are also eligible for receiving payments after meeting milestones such as speaking with a helpline coach.
Human research protection committees at New York University School of Medicine and the University of California Los Angeles (UCLA) David Geffen School of Medicine granted ethics approval. IRB#19-000 084.
NCT03979885.
在美国，吸烟仍然是导致死亡的首要可预防原因。戒烟治疗的利用率低仍然是降低吸烟率的主要障碍。经济激励是增加戒烟治疗的一种创新方法。本文将描述 Financial Incentives for Smoking Treatment II（FIESTA II）研究的原理和设计，这是一项随机对照试验，旨在评估基于目标和基于结果的经济激励措施对促进住院吸烟者戒烟的有效性和可行性。
我们正在招募在初次访谈前 30 天内吸烟且考虑戒烟的成年参与者。这些参与者将来自纽约市和洛杉矶两个服务不足社区的两家医院。他们将被随机分为三组。第一组为目标导向的经济激励加增强的常规护理，其中包括医院提供的关于戒烟、尼古丁替代疗法和戒烟热线转介的信息。第二组为基于结果的经济激励加增强的常规护理。第三组为仅增强的常规护理。随机分组后，将对参与者进行多次电话访谈，以评估戒烟情况。参与者每完成一次随访访谈可获得 20 美元，每完成一次戒烟测试可获得 30 美元。那些被随机分配到经济激励组的人可以额外获得 700 美元。基于结果的组中的参与者仅因表现出戒烟而获得付款，而基于目标的组中的参与者在达到里程碑（例如与热线教练交谈）后也有资格获得付款。
纽约大学医学院和加州大学洛杉矶分校（UCLA）大卫格芬医学院的人类研究保护委员会批准了伦理。IRB#19-000084。
NCT03979885。
